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The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute 
myeloid leukemia receiving grafts from unrelated donors 




Several studies provided evidence of a consistent antileukemic effect induced by cytomegalovirus (CMV) 
replication in acute myeloid leukemia (AML) patients receiving allogeneic hematopoietic stem cell 
transplantation (HSCT), however the use of antithymocyte globulin (ATG) as graft-versus-host disease 
prophylaxis, may potentially abrogate the protective effect of CMV infection. To address this issue, we 
retrospectively analyzed the risk of relapse in a cohort of 101 patients with AML who received grafts from 
an unrelated donor after a conditioning regimen including ATG. The cumulative incidence of CMV 
reactivation, evaluated by RT qPCR, was 59% at 12 months, and 93% of CMV reactivations occurred within 
the first 100 days post HSCT. The 5-year cumulative incidence of relapse in patients with CMV reactivation 
was 29% compared with 37% for patients without CMV reactivation, and the only factor associated with a 
reduced 5-year cumulative incidence of relapse was the disease status at HSCT (P < 0.001). In the 
multivariable model adverse cytogenetics (HR 2.42, 95% CI 1.02-5.72; P = 0.044) and acute GVHD (HR 3.36, 
95% CI 1.32-8.54; P =  0.011) were independent risk factors for reducing overall survival (OS), while the 
presence of chronic GVHD was associated with a better OS (HR 0.37, 95% CI 0.15-0.89; P = 0.027). CMV 
replication was not an independent risk factor for OS (HR 1.06, 95% CI 0.07-15.75; P = 0.965). In Conclusion, 
the results of present study suggest that relapse prevention in patients with AML receiving T-cell depleted 




A consistent number of studies recently published, raised the possibility of an association between 
cytomegalovirus (CMV) reactivation and a relapse risk reduction in patients with hematologic malignancies 
receiving hematopoietic stem cell transplantation (HSCT) [1-5]. Several factors were shown to influence the 
protective effect of CMV reactivation, including diagnosis [3], the intensity of the preparative regimen [6], 
and the use of T-cell depletion [7]. In this respect, patients with acute myeloid leukemia (AML) receiving 
myeloablative (MA) conditioning regimens appear to be those who might benefit from the antileukemic 
effect of CMV reactivation [6]. It is conceivable that the “virus-versus leukemia” effect promoted by CMV 
reactivation requires a robust T- or NK-cell immune response to elicit a graft-versus leukemia (GVL) effect. 
According to this observation, the use of in vivo T-cell depletion with alemtuzumab which typically depletes 
immune cells including NK cells may result in the abrogation of CMV-induced antileukemic effect [7]. On 
the other hand, very few data have been reported on the potential influence of antithymocyte globulin 
(ATG) in this context. The study by Manjappa et al. suggests that immune-suppression of ATG might 
contribute to mitigate the protective effect of CMV-specific T cells, although these data have not been 
confirmed by others [6]. Given the conflicting results, we aimed to investigate the influence of ATG on 




This is a retrospective study conducted in two Italian transplant Centers, including 101 adult patients with 
AML who received an allogeneic HSCT from an unrelated donor between July 2004 and February 2014 after 
a conditioning regimen incorporating ATG as part of graft-versus-host disease (GVHD) prophylaxis. The 
Institutional Review Board of each Center approved the study. 
 
Patients were selected for the analysis according to the following eligibility criteria: (1) all donors and 
recipients were typed at HLA loci A, B, C, DRB1, and DQB1 through high-resolution genotyping; (2) use of 
unmanipulated donor stem cells; (3) pharmacologic prophylaxis of GVHD including ATG; and (4) no use of 




A total of 83 patients (82%) received myeloablative preparative regimens consisting of i.v. busulphan (BU) 
combined with either high-dose cyclophosphamide (Cy) (n = 33), fludarabine (n = 21), or thiotepa and 
fludarabine (n = 6); high-dose Cy with 12.0 Gy TBI (n = 16); or thiotepa-Cy (n = 7). A reduced conditioning 
regimen (RIC) was administered to 18 patients (18%), consisting of thiotepa (10 mg/kg) and Cy (100 mg/kg) 
(n = 6); thiotepa-Cy and melphalan (n = 7); thiotepa and melphalan (n = 3); and fludarabine-melphalan 
(n = 2). 
 
Prophylaxis of GVHD consisted of cyclosporine (CSA) and short course methotrexate (MTX) in all subjects; 
ATG (Thymoglobulin) was administered to all patients at a dose of 5–7.5 mg/kg over two or three days (on 
days −4, −3, −2 or −3, −2). 
 
Transfusion support using leukocyte-filtered blood products was provided to maintain a hemoglobin ≥ 8 
g/dL and to prevent severe thrombocytopenia (≤ 15–20 × 109/L) 
 
CMV monitoring and pre-emptive therapy 
CMV reactivation was routinely monitored twice weekly during the inpatient post-transplantation course 
and weekly in the outpatient setting. All patients received acyclovir as antiviral prophylaxis up to 1 year 
after transplantation. CMV reactivation was pre-emptively treated with either i.v. ganciclovir or oral 
valganciclovir. Foscarnet was substituted in case of cytopenias. Antiviral induction therapy was continued 
for 14 days followed by maintenance treatment for 14 days or until two consecutive negative surveillance 
results were recorded. 
 
Definitions 
Monitoring for CMV infection/reactivation was done on whole blood specimens by molecular methods in 
90 patients. In particular, for specimens tested in 2004 and 2005, a home-made quantitative competitive 
PCR was used, as previously described [8]; any value >100 copies/mL was considered as CMV reactivation. 
Since 2006, specimens were tested by a commercially available real-time PCR assay (Nanogen Advanced 
Diagnostics, Elitech group, Milan, Italy; limit of detection, 2,000 copies/mL whole blood), as previously 
described [9]; CMV viral load >2,000 copies/mL was considered as CMV reactivation. CMV replication was 
detected by pp65 antigenemia positivity in 11 patients. pp65 antigenemia assay was performed on 
peripheral blood leukocytes (PBLs) applied to slides by cytocentrifugation of 200,000 cells each; a CMV 
reactivation was assumed if one or more cells with characteristic immunofuorescence/2 × 105 PBLs were 
detectable. 
 
Morphologic relapse of the leukemia was the primary outcome of patients transplanted in complete 
remission (CR) and progression of disease for patients who received grafts with active disease. Marrow 
examination was performed after HSCT at 30 days, 100 days, and at 6, 9, and 12 months thereafter. 
Cytogenetic risk was classified according to Cornelissen et al. [10]. 
 
The assessment and grading of acute and chronic GVHD were primarily based on clinical findings and 
followed the commonly accepted diagnostic criteria [11, 12]. Diagnosis was confirmed histologically 
whenever indicated and clinically possible. 
 
Study endpoints and statistical analysis 
The primary end point was the cumulative incidence of relapse (RI), while the secondary ones were the 
cumulative incidence of non-relapse mortality (NRM), the overall survival (OS), and the progression-free 
survival (PFS). The median follow-up for OS from transplantation was 60 months (range 1–118). 
 
The cumulative incidences of RI and NRM were estimated by the cumulative incidence function, comparing 
the curves of the main event (relapse), in the presence of a competing event (death without previous 
relapse) by the Gray test [13]. The univariate analyses were performed for the following prognostic factors: 
recipient age (>50 vs. ≤50 years), gender mismatch (any vs. none), HLA mismatch (≤9/10 vs. 10/10), CD34+ 
source (PBSC vs. bone marrow), conditioning regimen (myeloablative vs. RIC), disease status at 
transplantation (less than CR vs. CR2/3 vs. CR1), ATG dose (7–7.5 vs. 5–6 mg/kg), fluorescent in situ 
hybridization (FISH) abnormalities (high vs. standard risk), donor and recipient pre-transplantation CMV 
status (positive vs. negative), occurrence of acute GVHD Grade II–IV and/or chronic GVHD (any vs. none), 
recipient CMV post-transplantation reactivation status (any vs. none). The same covariates were then 
evaluated by the multivariate Fine and Gray competing risk regression model [14]. 
 
The OS and PFS curves were estimated by the Kaplan–Meier method, comparing the two arms by the log-
rank test [15]. OS and PFS were also analyzed by the Cox proportional hazards model, comparing the two 
arms by the Wald test and calculating 95% CIs; the disease status at transplantation, the occurrence of 
acute GVHD/chronic GVHD, and the CMV reactivation status were treated as time-dependent variables. 
 
Patient characteristics were tested using the Fisher's exact test for categorical variables and the Mann–
Whitney test for continuous ones. All reported P-values were two-sided, at the conventional 5% 
significance level. Data were analyzed as of August 2014 by R 3.1.1 package cmprsk (The R Foundation for 
Statistical Computing, Vienna-A; www.R-project.org). 
Results 
Patient characteristics 
A total of 60 patients (59%) had a positive q-CMV PCR (n = 49) or pp65 antigenemia (n = 11) at a median of 
35 days (range 12–389 days) after allogeneic HSCT, resulting in a cumulative incidence of CMV reactivation 
of 59% at 12 months. Nine-three percent of CMV reactivations (56/60) occurred within the first 100 days 
post HSCT. The median number of copies of CMV DNA and the median number of CMV pp65-antigen 
positive cells at the time of first CMV reactivation were 5012/mL (range 132–126,400 copies/mL) and 4 per 
2 × 105 PBLs (range 1–50 positive cells), respectively. Patient and transplant characteristics of the two 
cohorts with and without CMV reactivations are summarized in Table 1. Patients with and without CMV 
reactivation were similar relative to age, sex, cytogenetics, disease status at HSCT, HLA matching, 
preparative regimen, graft source, and onset of acute or chronic GVHD, while patients in the CMV 
reactivation group were more likely to have a pre-transplantation positive donor/recipient CMV serostatus. 
Table 1. Patient, Donor, and Transplant Characteristics According to Post-Transplantation CMV Reactivation 
 
 
CMV reactivation and preemptive antiviral therapy 
Overall, 53 patients received pre-emptive treatment consisting of valganciclovir in 32 cases, ganciclovir in 
13 cases, and foscarnet in 4 cases; 4 patients, who were considered at high risk of CMV disease due to 
concomitant steroid treatments, received a combination of foscarnet and ganciclovir/valganciclovir. Seven 
patients with a low or spontaneous decrease of CMV viral load did not receive any specific preemptive 
treatment. 
CMV reactivation and risk of relapse after allogeneic HSCT 
Overall, 30 patients (30%) relapsed at a median time of 327 days (range 63–1,229 days) after HSCT, 
corresponding to a cumulative incidence of relapse of 25%, 32%, and 32% respectively at 1, 3, and 5 years 
post-transplantation. The cumulative incidence of relapse in patients with CMV reactivation was 19%, 29%, 
and 29% compared with 34%, 37%, and 37% for patients without CMV reactivation at 1 year, 3 years, and 5 
years, respectively (Fig. 1A). The only factor affecting the 5-year cumulative incidence of relapse was an 
advanced disease phase at HSCT both in univariate (Table 2) and multivariate cumulative incidence analyses 
(HR 2.12, 95% CI 1.38–3.27; P < 0.001). In a subgroup analysis of the 83 patients who received a 
myeloablative regimen, the cumulative incidence of relapse was 32% in patients with CMV infection 
compared to 42% in patients without CMV infection (P = 0.313). In order to exclude the possibility that 
patients with active disease were blunting the protective effect of CMV reactivation, we evaluated the risk 
of relapse in 85 patients who received the graft in CR: the 5-year cumulative incidence of relapse was not 
statistically different in patients with CMV reactivation as compared to patients without CMV reactivation 
(23% vs. 30%, P = 0.395). 
 
 





Effect of CMV reactivation on overall survival and nonrelapse mortality 
After a median follow-up of 60 months, 56 patients are alive and 45 died, 27 with progressive disease and 
18 because of NRM. The Kaplan–Maier estimate of OS was 68%, 52%, and 52% at 1 year, 3 years, and 5 
years, respectively. Figure 1B shows the OS stratified by CMV reactivation. An advanced disease phase at 
HSCT and the presence of acute Grade II–IV GVHD were the two factors associated with a reduced OS, 
while there was a non-significant trend toward a better OS for patients developing chronic GVHD (Table 2). 
The cumulative incidence of NRM at 100 days and 1 year was 10% and 16%, respectively. Figure 1C shows 
the cumulative incidence of NRM stratified by CMV reactivation. The presence of acute GVHD was 
significantly associated with an increased NRM rate. CMV reactivation was not associated with different OS 
or NRM rates (Table 2). In the multivariable model, adverse cytogenetics (HR 2.42, 95% CI 1.02–5.72; 
P = 0.044) and acute GVHD (HR 3.36, 95% CI 1.32–8.54; P = 0.011) were independent risk factors for 
reducing OS, while the presence of chronic GVHD was associated with a better OS (HR 0.37, 95% CI 0.15–




Between 1987 and 2014, five studies were published providing evidence of a consistent antileukemic effect 
elicited by CMV infection in patients with AML receiving allogeneic HSCT [2, 3, 6, 16, 17]. However, whether 
in vivo T-cell depletion might potentially mitigate the beneficial effect of CMV reactivation is still a matter 
of debate. Our retrospective analysis including a large cohort of patients with AML, who received grafts 
from a MUD after a conditioning incorporating ATG, showed that pre-transplantation disease status was 
the only factor affecting the final outcome, whereas CMV replication was not recognized as an independent 
variable for reduced risk of relapse. Our findings are in line with the results of Manjappa et al. showing that 
the antileukemic effect of CMV reactivation was not detectable in 58 patients who received a RIC regimen, 
possibly because the majority (44 out of 58) of these patients received ATG as part of the preparative 
regimen [6]. On the other hand, we did not observe any effect of the intensity of the preparative regimen 
on the risk of relapse, although it should be emphasized that given the small number of patients receiving 
RIC, our finding should be interpreted with caution. It is interesting to note that in our study, patients with 
CMV reactivation appear to have leukemic relapse later than those who did not have CMV infection. The 
effect of early CMV replication on leukemic relapse has been recently investigated by others [3, 17]. Since 
most relapses occur during the early post-HSCT phase when the defect of immune reconstitution may 
translate into a blunting period of GVL effects, it has been hypothesized that CMV replication may offset 
the lack of an immune-mediated antileukemic effect [3, 17, 18]. Similarly, Green at al. showed that CMV 
reactivation in patients with AML marginally decreases the risk of relapse by day 100, but was not 
associated with a reduced risk of recurrence by 1 year [3]. 
 
The mechanism by which CMV exerts the antileukemic effect has not been clarified, and this makes even 
more difficult to define the role of ATG in this context. It has been demonstrated that γδT cells, in particular 
the subset Vδ2NEG γδT cells, are involved in the immune response against CMV and in the final clearance 
of the virus [19]. Furthermore, expanded γδT cells have been shown to be cytotoxic to cancer cells in vitro 
[20], and more recently Scheper et al. have demonstrated that CMV-induced γδT cells are capable of cross-
recognizing residual leukemic blasts, supporting the hypothesis that CMV replication might have an 
unexpected beneficial effect on the risk of leukemic relapse [21]. The use of ATG has been recognized as 
one of the major risk factors for CMV infection after HSCT, and several studies have analyzed the immune 
reconstitution kinetics following the administration of ATG [22]. Nevertheless, there are no data evaluating 
specifically the impact of ATG on γδT cells subset. Alternatively, Foley et al. showed that CMV replication 
may induce the expansion of NK cells expressing NKG2C which were associated with a potent IFNγ 
production, and this population of NK cells may contribute to the elimination of residual leukemic cells [23]. 
ATG is known to have a moderate effect on the reconstitution kinetic of NK cells, but we do not have data 
regarding the possible influence on NKG2C+ NK cells, as documented by the fact that, in the study of Foley 
et al., only a minority of patients (7 out of 73) received ATG as part of the preparative regimen [23]. The 
disease status at the time of transplant has emerged as the major determinant for the final clinical 
outcome of our patients. This is not surprising if we consider that one-third of the patients were in 
advanced phase of disease (beyond CR1/active disease) at the time of transplant, and this might have 
obscurated the CMV-induced antileukemic effect. In addition, it should be underscored that 14% of our 
HSCT recipients were CMV seronegative and this might have contributed to alter the impact of CMV 
reactivation on relapse. In fact, the GVL effect induced by CMV reactivation seems to be maximized in 
seropositive patients, because donor-derived T cells specifically directed to CMV could be cytotoxic to 
leukemic blasts harboring CMV [24]. 
 
In conclusion, the results of our study suggest that immune suppression with ATG might be able to 
abrogate the protective effect of CMV infection described in patients with AML, underlining the need for 





1 Lönnqvist B, Ringdèn O, Ljungman P, et al. Reduced risk of recurrent leukaemia in bone 
marrow transplant recipients after cytomegalovirus infection. Br J Haematol 1986;63:671.  
2 Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replication 
after transplantation is associated with a decreased relapse risk: Evidence for a putative virus-
versus-leukemia effect in acute myeloid leukemia patients. Blood 2011;118:1402–1412.  
3 Green ML, Leisenring WM, Kie H, et al. CMV reactivation after allogeneic HCT and relapse 
risk: Evidence for early protection in acute myeloid leukemia. Blood 2013;122:1316–1324.  
4 Ito S, Pophali P, CO W, et al. CMV reactivation is associated with a lower incidence of 
relapse after allo-SCT for CML. Bone Marrow Transplant 2013;48:1313–1316.  
5 Mariotti J, Maura F, Spina F, et al. Impact of cytomegalovirus replication and 
cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic 
stem cell transplantation. Biol Blood Marrow Transplant 2014;20:881–903.  
6 Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, et al. Protective effect of 
cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in 
acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow 
Transplant 2014;20:46–52.  
7 Thomson KJ, Mackinnon S, Peggs KS. CMV-specific cellular therapy for acute myeloid 
leukemia? Blood 2012;119:1088–1090.  
8 Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses 
reactivation in active crhon disease. Inflamm Bowel Dis 2007;13:896–902.  
9 Costa C, Balloco C, Sidoti F, et al. Evaluation of CMV-specific cellular immune response by 
EliSPOT assay in kidney transplant patients. J Clin Virol 2014;61:523–528.  
10 Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European leukemia net AML working 
party consensus statement an allogenic HSCT for patients with AML in remission: On 
integrated-risk adapted approach. Nat Rev Clin Oncol 2012;9:579–590.  
11 Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft versus-host disease in 
human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295–
304.  
12 Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus 
development project on criteria for clinical trials in chronic graft-versus-host disease. I. 
Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–956.  
13 Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing 
risk. Ann Stat 1988;16:1141–1154.  
14 Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. 
J Am Statist Assoc 1999;94:496–509.  
15 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat 
Assoc J 1958;53:457–481.  
16 Jacobsen N, Badsberg JH, Lonqvist B, et al. Graft-versus-leukaemia activity associated with 
cytomegalovirus antibody positive bone marrow donors in acute myeloid leukemia. Lancet 
1987;456–457.  
17 Jang JE, Kim SJ, Cheong J-W, et al. Early CMV replication and subsequent chronic GVHD 
have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann 
Hematol 2015;94:275–282.  
18 Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor 
effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013;31:1530–1538.  
19 Knight A, Madrigal AJ, Grace S, et al. The role of Vdelta2-negative gammadelta T cells 
during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood 
2010;116:2164–2172.  
20 Scotet E, Martinez LO, Grant E, et al. Tumor recognition following Vgamma9Vdelta2 T cell 
receptor interactions with a surface F1-ATPase-related structure and apolipoprotein a-I. 
Immunity 2005;22:71–80.  
21 Scheper W, van Dorp S, Kersting S, et al. γδT cells elicited by CMV reactivation after allo-
SCT cross-recognize CMV and leukemia. Leukemia 2013;27:1328–1338.  
22 Schmidt-Hieber M, Schwarck S, Stroux A, et al. Immune reconstitution and cytomegalovirus 
infection after allogeneic stem cell transplantation: The important impact of in vivo T cell 
depletion. Int J Hematol 2010;91:877–885.  
23 Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic 
transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with 
potent function. Blood 2012;119:2665–2674.  
24 Barrett AJ. CMV: When bad viruses turn good. Blood 2011;118:1193–1194. 
